Gilead Provides Update on U.S. Indication for Trodelvy® in …
2 days ago · Back. Foster City, Calif., October 18, 2024 – Gilead Sciences, Inc. today announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy® (sacituzumab govitecan-hziy; SG) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing ...
Gilead Sciences Voluntarily Pulls Drug for Bladder Cancer After …
2 days ago · By Frank Vinluan on October 18, 2024. Gilead Sciences is voluntarily withdrawing cancer drug Trodelvy from the U.S. market as a treatment for advanced cases of urothelial carcinoma, a move that ...
Gilead withdraws bladder cancer drug in US after failed trial
2 days ago · GILD. (Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a ...
Gilead withdraws Trodelvy in bladder cancer - Yahoo Finance
2 days ago · To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Recommended Reading . ... Trodelvy is a key part of Gilead’s foray into cancer treatment. An antibody ...
Gilead withdraws bladder cancer drug in US after failed trial
2 days ago · Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...
Gilead withdraws Trodelvy in bladder cancer after trial flop
2 days ago · Following the setback in that study, called EVOKE-01, Gilead recognized an impairment charge of $2.4 billion. Trodelvy was the crown jewel in Gilead’s $21 billion acquisition of Immunomedics in ...
Gilead to withdraw Trodelvy accelerated approval for bladder …
2 days ago · Gilead Sciences announced its intention to voluntarily withdraw the accelerated approval for sacituzumab govitecan-hziv for treatment of certain patients with advanced bladder cancer.The ...
Gilead to Withdraw U.S. Accelerated Approval for Trodelvy in …
2 days ago · Gilead reported worldwide Trodelvy sales of $628 million for the first six months of the year, representing less than 5% of the company's revenue of more than $13.6 billion for the period.
U.S. FDA Grants Accelerated Approval to Trodelvy ... - Gilead Sciences
Apr 13, 2021 · The accelerated approval was based on data from the international Phase 2, single-arm TROPHY study. Of the 112 patients who were evaluable for efficacy, 27.7% of those treated with Trodelvy responded to treatment, with 5.4% experiencing a complete response and 22.3% experiencing a partial response.
Gilead to pull Trodelvy U.S. indication on trial setback - MSN
Gilead (NASDAQ:GILD) on Friday announced plans to voluntarily withdraw a U.S. indication for its antibody-drug conjugate Trodelvy in bladder cancer after a late-stage confirmatory trial for the ...